Clinical Trial Update: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with or without trebananib for recurrent brain tumors has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasm
• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma
• Oligodendroglioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Trebananib (trebananib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Giant Cell Glioblastoma, Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-27